Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Roblin

Showing results (81-90 of 82) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 82 results.
Alimentary Pharmacology & Therapeutics|December 19, 2017
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohortS Tadbiri, L Peyrin-Biroulet, M Serrero, et al.
Gut|January 6, 2017
Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximabD Laharie, A Bourreille, J Branche, et al.
Pageof 9

Showing results (81-90 of 82) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 82 results.
Alimentary Pharmacology & Therapeutics|December 19, 2017
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohortS Tadbiri, L Peyrin-Biroulet, M Serrero, et al.
Gut|January 6, 2017
Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximabD Laharie, A Bourreille, J Branche, et al.
Pageof 9